Thursday, December 24, 2020 8:08:19 AM
From the PR - the key is this news.
Can we get this news before year end?
Will it be positive? If not, it will rank.
In reality, this is not a Covid play and no valuation is included in current price but bad news impacts the SP anyways.
In fact, for the severe Covid cases, there are only handful drugs that actually are under trial at late stage - RDHL, CYDY, MRK, HGEN and RLFTF
However, CYDY is ahead of everyone as the enrollment is complete and P3 results expected by last week of Jan
MRK P3 enrollment is going on and RDHL P2/3 enrollment is going on.
“Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib”
Can we get this news before year end?
Will it be positive? If not, it will rank.
In reality, this is not a Covid play and no valuation is included in current price but bad news impacts the SP anyways.
In fact, for the severe Covid cases, there are only handful drugs that actually are under trial at late stage - RDHL, CYDY, MRK, HGEN and RLFTF
However, CYDY is ahead of everyone as the enrollment is complete and P3 results expected by last week of Jan
MRK P3 enrollment is going on and RDHL P2/3 enrollment is going on.
“Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib”
Recent RDHL News
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/27/2026 12:18:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 12:04:19 PM
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights • PR Newswire (US) • 04/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 10:09:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 12:02:19 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:07 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 05:14:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 02:00:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:01:02 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2026 12:00:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/27/2026 12:00:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/22/2026 09:06:45 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 01/22/2026 09:04:43 PM
